Keyßer Gernot
Department für Innere Medizin, Klinik für Innere Medizin II, Universitätsklinikum Halle (Saale), Ernst-Grube-Str. 40, 06120, Halle (Saale), Deutschland.
Z Rheumatol. 2020 Jun;79(5):437-445. doi: 10.1007/s00393-020-00790-7.
Mesenchymal stromal or stem cells (MSC) possess strong immunomodulatory properties. Due to their impressive potential to differentiate into various cell types they are capable of inducing mechanisms of tissue repair. Experimental data have demonstrated impaired MSC function in several rheumatic diseases in vitro; however, the relevance of these phenomena for the pathogenesis of rheumatic disorders has not been convincingly demonstrated. Nevertheless, allogeneic MSC transplantation (MSCT), and possibly autologous MSCT as well, could prove to be an interesting instrument for the treatment of autoimmune rheumatic diseases. The first clinical trials have demonstrated positive effects in systemic lupus erythematosus, systemic sclerosis and Sjogren's syndrome; however, questions regarding the long-term benefits and safety as well as the best source, the optimal cultivation technique and the most effective way of application of MSC are still unanswered.
间充质基质细胞或干细胞(MSC)具有强大的免疫调节特性。由于它们具有分化为各种细胞类型的巨大潜力,因此能够诱导组织修复机制。实验数据表明,在体外多种风湿性疾病中MSC功能受损;然而,这些现象与风湿性疾病发病机制的相关性尚未得到令人信服的证实。尽管如此,同种异体MSC移植(MSCT)以及可能的自体MSCT,可能被证明是治疗自身免疫性风湿性疾病的一种有趣手段。首批临床试验已在系统性红斑狼疮、系统性硬化症和干燥综合征中显示出积极效果;然而,关于MSC的长期益处和安全性以及最佳来源、最佳培养技术和最有效应用方式等问题仍未得到解答。